Summary
Edwards Lifesciences Corporation reported net sales of $191.9 million for the three months ended March 31, 2001, a decrease of 15.1% compared to $226.0 million in the prior year period. This decline was primarily driven by a change in accounting for sales in Japan and the divestiture of its perfusion products line. However, excluding these items and foreign currency impacts, total net sales saw a slight decrease of 0.3%. The company's operating income increased to $27.0 million from $24.1 million, while net income decreased to $12.7 million ($0.21 per diluted share) from $17.3 million in the prior year, impacted by a one-time charge related to the adoption of SFAS No. 133. The company continues to invest in research and development, particularly in its strong cardiac surgery segment, which saw a 7.5% increase in sales. Key financial highlights include a stronger gross profit margin of 49.9% compared to 47.6% in the prior year, attributed to a favorable product mix and divestiture of lower-margin businesses. The balance sheet shows total assets of $1,102.9 million and total stockholders' equity of $464.0 million as of March 31, 2001. Cash flow from operations was negative $7.3 million for the quarter, a significant decrease from the prior year's positive $18.5 million, mainly due to changes in working capital. The company ended the quarter with $17.9 million in cash and cash equivalents. Management believes current liquidity is sufficient to meet obligations.
Key Highlights
- 1Net sales decreased by 15.1% to $191.9 million in Q1 2001 compared to $226.0 million in Q1 2000, impacted by Japan accounting changes and divestitures.
- 2Operating income increased to $27.0 million in Q1 2001, up from $24.1 million in Q1 2000.
- 3Net income decreased to $12.7 million ($0.21/diluted share) in Q1 2001, down from $17.3 million in Q1 2000, partly due to a $1.5 million charge from adopting SFAS No. 133.
- 4Gross profit margin improved to 49.9% in Q1 2001 from 47.6% in Q1 2000, driven by a favorable product mix and divestitures of lower-margin businesses.
- 5Cardiac Surgery product sales grew by 7.5% to $84.9 million, indicating strength in this core segment.
- 6Cash flow from operating activities turned negative at ($7.3) million for Q1 2001, compared to positive $18.5 million in Q1 2000, due to increased inventory and receivables.
- 7The company adopted SFAS No. 133 effective January 1, 2001, resulting in a $1.5 million after-tax reduction in net income and a $5.4 million after-tax reduction in Accumulated Other Comprehensive Income.
- 8Total stockholders' equity increased to $464.0 million as of March 31, 2001, from $439.6 million as of December 31, 2000.